Short Interest in Actuate Therapeutics, Inc. (NASDAQ:ACTU) Declines By 40.4%

Actuate Therapeutics, Inc. (NASDAQ:ACTU) was the recipient of a large decline in short interest in July. As of July 31st, there was short interest totaling 450,180 shares, a decline of 40.4% from the July 15th total of 754,754 shares. Approximately 4.5% of the shares of the company are sold short. Based on an average trading volume of 155,092 shares, the short-interest ratio is currently 2.9 days.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Actuate Therapeutics in a research report on Wednesday, June 24th. Wall Street Zen cut shares of Actuate Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 23rd. Rodman & Renshaw initiated coverage on shares of Actuate Therapeutics in a report on Thursday, July 30th. They issued a “buy” rating and a $6.00 price objective for the company. Finally, HC Wainwright reiterated a “buy” rating on shares of Actuate Therapeutics in a research report on Wednesday, June 10th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $13.67.

Actuate Therapeutics Stock Down 2.0%

ACTU opened at $0.99 on Tuesday. The business has a fifty day simple moving average of $1.47 and a 200-day simple moving average of $2.44. The firm has a market cap of $23.69 million, a PE ratio of -1.14 and a beta of 0.78. Actuate Therapeutics has a fifty-two week low of $0.90 and a fifty-two week high of $9.22.

Actuate Therapeutics (NASDAQ:ACTU) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.01. On average, equities research analysts anticipate that Actuate Therapeutics will post -0.86 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Sfmg LLC grew its holdings in shares of Actuate Therapeutics by 17.6% during the 4th quarter. Sfmg LLC now owns 20,000 shares of the company’s stock valued at $122,000 after acquiring an additional 3,000 shares in the last quarter. Barclays PLC boosted its stake in shares of Actuate Therapeutics by 68.6% during the 4th quarter. Barclays PLC now owns 14,946 shares of the company’s stock worth $91,000 after acquiring an additional 6,081 shares in the last quarter. State Street Corp grew its holdings in Actuate Therapeutics by 12.8% during the fourth quarter. State Street Corp now owns 56,290 shares of the company’s stock valued at $344,000 after purchasing an additional 6,395 shares during the last quarter. ABS Direct Equity Fund LLC acquired a new position in Actuate Therapeutics in the 4th quarter valued at $40,000. Finally, Wells Fargo & Company MN grew its position in shares of Actuate Therapeutics by 48.8% in the fourth quarter. Wells Fargo & Company MN now owns 20,146 shares of the company’s stock valued at $123,000 after purchasing an additional 6,604 shares during the last quarter.

Actuate Therapeutics Company Profile

Actuate Therapeutics (NASDAQ: ACTU) is a clinical-stage oncology company focused on the discovery and development of targeted therapies designed to address key drivers of tumor growth and survival. Headquartered in South San Francisco, California, the company applies a precision medicine approach to identify novel molecular targets and develop small-molecule agents that have the potential to improve outcomes for patients with difficult-to-treat cancers.

The company’s lead asset, atuveciclib, is a selective, oral CDK9 inhibitor being evaluated in a Phase 1 clinical trial for patients with acute myeloid leukemia and advanced solid tumors.